ArticleThe Journal of antimicrobial chemotherapy2025
Piperacillin dosing in pediatric patients and augmented renal clearance: are current guidelines sufficient to achieve therapeutic concentration coverage?
Article in The Journal of antimicrobial chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Achieving therapeutic antibiotic levels during intermittent dosing of meropenem and piperacillin-tazobactam in critically ill children: the ATACC study.Antimicrobial agents and chemotherapy · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAppropriate dosing of piperacillin/tazobactam is crucial for hospitalized children and might be a challenge in case of augmented renal clearance. This study assessed the appropriateness of piperacillin dosing regimens recommended to attain pharmacokinetic/pharmacodynamic targets by pediatric guidelines using a population pharmacokinetic approach.
methodsA population pharmacokinetic model for piperacillin was developed using therapeutic drug monitoring observations collected in hospitalized children between 2012 and 2021. Subsequently, simulations were performed to evaluate whether dosing regimens recommended by various pediatric guidelines achieved the pharmacodynamic target [i.e. maintaining free piperacillin plasma concentrations above the minimum inhibitory concentration for 100% of the dosing interval (100% fT > MIC)] in case of augmented, normal and moderately impaired renal functions.
resultsThe model best describing our 386 concentration values in 104 patients was a two-compartment model with allometric scaling of pharmacokinetic parameters based on bodyweight. Renal function also influenced clearance. Simulations revealed a risk of underdosing in patients with a creatinine clearance above 50 mL/min/1.73 m2 when piperacillin was administered as intermittent infusions, according to most guidelines. In contrast, continuous infusions consistently achieved the pharmacodynamic target even for MIC close to the limit of susceptibility.
conclusionThis study highlights the critical impact of renal function on piperacillin pharmacokinetics in pediatric patients. Continuous infusion regimens are necessary to ensure optimal drug exposure and efficacy, particularly in patients with augmented creatinine clearance. These results emphasize the need to revise pediatric dosing strategies considering a broader range of renal function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.